Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...
Donald Trump and his advisers are about to launch a consequential battle against unhealthy food producers and the ...
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...
CNBC's Angelica Peebles talks to Structure Therapeutics CEO Ray Stevens about the obesity landscape and why there's still ...
Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...
The popularity of GLP-1R drugs has catapulted the treatment landscape of obesity into the spotlight. Reformation for the ...
Eli Lilly (NYSE:LLY) CEO Dave Ricks said Monday that the company's GLP-1 weight-loss pill orforglipron could receive FDA approval as soon as early 2026. In an interview with Bloomberg TV ...
Deloitte notes that many companies are trying to capture a share of the $200 billion GLP-1 drug market. Beyond obesity, potential indications for these drugs include sleep apnea, addiction ...
Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...